# Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population

> **NCT01877421** · PHASE1,PHASE2 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 135 (actual)

## Conditions studied

- Plaque
- Gingivitis

## Interventions

- **DRUG:** 2 mg KSL-W
- **DRUG:** 4 mg KSL-W
- **DRUG:** 6 mg KSL-W
- **DRUG:** 10 mg KSL-W
- **DRUG:** 20 mg KSL-W
- **DRUG:** 30 mg KSL-W
- **DRUG:** 50 mg KSL-W
- **DRUG:** 75 mg KSL-W
- **DRUG:** 100 mg KSL-W
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01877421
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-25
- **Primary completion:** 2015-08-25
- **Final completion:** 2016-03
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01877421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01877421, "Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01877421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*